August 28, 2012 |
Since tissue plasminogen activator (tPA) was approved by the Food and Drug Administration in 1996 for the dissolution of blood clots in the brain that cause strokes, it has been the primary treatment for stroke victims. But it has several limitations. In most cases, it must be used within three hours after the stroke to be effective, although in some cases the crucial window can be extended to 4.5 hours. It is also often not effective in dissolving larger blood clots. On 2004, the FDA approved the first mechanical system for removing clots from the brain, the Merci Retrieval System.
January 27, 2003 |
Eating vegetables with your meat may take the edge off the damage the fat can do, at least in the short run. An Italian study of healthy young men and women found that adding tomatoes, carrots and peppers, which are good sources of antioxidants, to a high-fat meal lessened its negative effect on the cells lining the blood vessels.
July 24, 1996 |
* A typical square inch of body skin includes about 19 million cells, including an average of 625 sweat glands, 90 sebum or oil glands, 65 hair follicles, 19,000 sensory cells and about 12 to 13 feet of microscopic blood vessels. * Goose bumps are caused by smooth muscles that are concentrated around hair follicles. Under stimulation these muscles contract. This can be a reaction to cold or an evolutionary "flight or fight" response.
June 8, 1998 |
A heart blood vessel that was largely blocked caused the chest pains that put Gov. Jim Edgar in the hospital over the weekend, doctors said. The injury to the tiny blood vessel was characterized as a bruise to the heart that left no major or long-term damage. Dr. James Dove, president of the Prairie Heart Institute at St. John's Hospital, said the problem would be treated with medicine rather than surgery.
September 18, 1996
Gensia Laboratories Ltd. said it signed a license to market a generic treatment for blocked blood vessels in the lung or heart. Gensia's deal with Microbix Biosystems Inc. of Toronto provides for the Irvine drug maker to handle regulatory approval, manufacturing, packaging and sales of the treatment, ThromboClear, in the U.S. Microbix will develop and supply the active ingredient, urokinase, a protein enzyme that facilitates the dissolution of blood clots. Gensia is a unit of Gensia Inc.
CALIFORNIA | LOCAL
July 27, 1994
Researchers at UCI Medical Center are looking for 25 volunteers to participate in a study of a drug that may relieve a potentially debilitating leg condition. People with the condition, called intermittent claudication, experience aching, cramping and sometimes severe pain when they walk, but feel fine while at rest, research coordinator Judith Hopkins said. The symptoms are caused by atherosclerosis, a narrowing in the blood vessels due to plaque or fatty deposits.
CALIFORNIA | LOCAL
June 19, 1989 |
A new approach to gene replacement therapy in animals and, eventually, in humans has been developed independently by two groups of researchers. The groups reported last week in the journal Science that they had used a special virus to insert the gene for a protein into cells isolated from the lining of blood vessels, then reintroduced the cells into pigs and dogs. The engineered cells then colonized the interior of blood vessels and began producing the new protein. In the past, researchers have speculated about using bone marrow cells, the source of blood cells, for gene replacement therapy.
October 25, 2012 |
The Food and Drug Administration on Thursday warned parents and pediatricians about the dangers of swallowing over-the-counter eyedrops and nasal decongestants by children age 5 and younger. The agency cited 96 cases of serious illness resulting from accidental swallowing of the products, with 53 hospitalizations. There were, fortunately, no deaths. The eyedrops, which are sold under a wide variety of brand and generic names -- including Visine, Opcon-A, Naphcon, Afrin, Dristan, Mucinex and Sudafed -- contain either tetrahydrozoline, oxymetazoline of naphazoline.
January 10, 1985 |
Microsurgeons predict that within 15 years they will be able to perform routine operations on fetuses developing in the womb and to negate the need for transplant surgery by repairing hearts, kidneys and livers before returning the organs to the body. "Microsurgical research and techniques being developed around the world today will radically transform the health care profession and hospitals before the year 2000," said Dr. Sebastian Arena, director of Mercy Hospital's microsurgery laboratory.
March 5, 1991 |
A tiny diamond-tipped cutting tool spinning 200,000 times per minute successfully tunneled through deposits clogging arteries in 95% of 315 patients tested, scientists reported. "It has been an exceedingly useful device to treat blood vessels in a different way," said Dr. Maurice Buchbinder, a cardiologist at the University of California, San Diego. Side effects were minimal, Buchbinder said in a report at the annual meeting of the American College of Cardiology in Atlanta. Dr.